A Controlled Trial of Erenumab for Episodic Migraine

In this study, researchers evaluated erenumab for preventing episodic migraine. Erenumab is a monoclonal antibody that inhibits a specific receptor. Patients received a monthly injection of either 70 mg, 140 mg, or placebo. The trial lasted for 6 months with 955 patients enrolled. The primary goal was to measure changes in migraine days. At baseline, patients averaged 8.3 migraine days each month. By months 4 through 6, the 70 mg group had 3.2 fewer days. The 140 mg group reported 3.7 fewer migraine days. In contrast, the placebo group saw a reduction of only 1.8 days. Additionally, 43% of the 70 mg group and 50% of the 140 mg group had a significant reduction in monthly migraine days. Erenumab also decreased medication usage and improved daily functioning. Side effects were similar in both erenumab and placebo groups. Further research is needed on long-term safety and effectiveness. Clinical relevance: Erenumab significantly reduces migraine frequency and improves daily activities for patients.